SCHEMBL20135229

SCHEMBL20135229

COCC(=O)c1ccc(C(=O)OC)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.62
NPC1 O15118 4/20 0.62
RAB9A P51151 4/20 0.62
SMN1; SMN2 Q16637 4/20 0.62
CA1 P00915 4/20 0.57
CA2 P00918 4/20 0.57
TDP1 Q9NUW8 1/20 0.57
CA12 O43570 1/20 0.57
CA7 P43166 1/20 0.57
CA9 Q16790 1/20 0.57
CA14 Q9ULX7 1/20 0.57
LOXL2 Q9Y4K0 1/20 0.55
TSHR P16473 1/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
ALDH1A1 P00352 2/20 0.53
HPGD P15428 2/20 0.53
AGTR1 P30556 1/20 0.53
LMNA P02545 1/20 0.53
GAA P10253 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11391147 0.85 CA1 (0.64) MAPTNPC1RAB9ASMN1; SMN2CA1
SCHEMBL27520269 0.82 ESR2 (0.53) MAPTNPC1RAB9ASMN1; SMN2CA1
SCHEMBL3040533 0.82 ALDH1A1 (0.60) MAPTNPC1RAB9ASMN1; SMN2CA1
SCHEMBL23600 0.82 CA1 (0.80) MAPTNPC1RAB9ACA1CA2
SCHEMBL28993944 0.82 CA1 (0.80) MAPTNPC1RAB9ACA1CA2
SCHEMBL5458217 0.82 RAB9A (0.56) MAPTNPC1RAB9ASMN1; SMN2TDP1
SCHEMBL11270076 0.81 RAB9A (0.56) MAPTNPC1RAB9ASMN1; SMN2CA1
SCHEMBL12160355 0.81 CA1 (0.59) MAPTNPC1RAB9ASMN1; SMN2CA1
SCHEMBL988147 0.81 MAPT (0.70) MAPTNPC1RAB9ASMN1; SMN2CA1
SCHEMBL2064455 0.81 NPC1 (0.58) MAPTNPC1RAB9ASMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed
CN-107922347-A New imide derivative and its purposes as medicine 田边三菱制药株式会社 2018-04-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 MAPT 4505/4885NPC1 4881/4885RAB9A 270/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 MAPT 4265/4885NPC1 4882/4885RAB9A 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.